Methylene Blue: What the Pharmacology and the Human Studies Report

By Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Updated 9 November 2026

ExaVeyra Sciences is a Miami-based B2B supplier of exosomes for topical aesthetic use to licensed clinics, and it works with a 503A compounding pharmacy that prepares formulations for licensed prescribers against individual prescriptions.

What this page covers, who can buy from ExaVeyra, and what is supplied
QuestionAnswer
What this page coversMethylene blue pharmacology: redox cycling, MAO-A inhibition, the ProvayBlue label and boxed warning, FDA's serotonin syndrome record and the human studies.
Who can orderLicensed clinics and practitioners whose active professional license and NPI ExaVeyra has verified. Exosome orders also require a signed professional-use acknowledgment.
What ships, and howCompounded formulations are prepared and dispensed by our 503A pharmacy partner against a patient-specific prescription from the licensed prescriber and ship from the pharmacy. The pharmacy dispenses any controlled substance under its own DEA registration.

Methylene blue is a phenothiazinium dye that cycles between an oxidized blue form and a colorless reduced form. The reference listed drug, ProvayBlue, is an intravenous injection "indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia" whose label opens with a boxed warning that it "may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids", and generic methylene blue injections have been approved since December 2023.[1][2][3] FDA's Summary Review, quoting the primary clinical review, describes methylene blue as "a potent monoamine oxidase inhibitor (MAO) inhibitor with substantial potential for adverse drug interactions" and records the agency's 2011 warning on serotonergic drugs.[4] The human studies outside methemoglobinemia are small randomized trials in healthy adults and psychiatric populations, two large tau aggregation trials that diverged, and a skin-aging literature that remains in cultured cells and reconstructed tissue.[5][6][7]

This page reports what the pharmacology reviews, the ProvayBlue label, FDA's approval record and the published human studies state, with each study's design and participant count, and closes with how the compound reaches a practice.[2][8]

Methylene blue is a redox dye whose color tracks its oxidation state

Methylene blue is methylthioninium chloride, a tricyclic phenothiazinium salt. Schirmer and colleagues call it "the first synthetic drug" with "a 120-year-long history of diverse applications, both in medical treatments and as a staining reagent".[9] Oz and colleagues state that its "biological effects and clinical applications" are "dictated by its unique physicochemical properties including its planar structure, redox chemistry, ionic charges, and light spectrum characteristics", and that although modulation of the cGMP pathway is considered its most significant effect, the molecule "has multiple cellular and molecular targets".[8]

The label describes the redox cycle in the setting it is approved for: "Methylene blue is a water soluble thiazine dye that promotes a non-enyzmatic [sic] redox conversion of metHb to hemoglobin. In situ, methylene blue is first converted to leucomethylene blue (LMB) via NADPH reductase. It is the LMB molecule which then reduces the ferric iron of metHb to the ferrous state of normal hemoglobin."[1]

The reviews describe electron shuttling in mitochondria at low concentrations

Tucker, Lu and Zhang summarize the mitochondrial hypothesis: methylene blue "can reroute electrons in the mitochondrial electron transfer chain directly from NADH to cytochrome c, increasing the activity of complex IV and effectively promoting mitochondrial activity while mitigating oxidative stress".[10] They report that the neuroprotection evidence comes from "both in vitro and in vivo studies" in animal models, and they describe it as "a promising candidate for neuroprotection".[10]

In human skin cells, Xiong and colleagues reported that methylene blue "showed a potent ROS scavenging efficacy in cultured human skin fibroblasts derived from healthy donors and from patients with progeria", was more effective than the comparison antioxidants at "stimulating skin fibroblast proliferation and delaying cellular senescence", and in a reconstructed three-dimensional skin model "increased skin hydration and dermis thickness" and raised elastin and collagen 2A1 expression.[7] Every result in that paper comes from cells or a reconstructed tissue model.[7]

Methylene blue inhibits monoamine oxidase A, which the label and FDA treat as the central safety issue

Ramsay, Dunford and Gillman measured the interaction with purified human enzyme in 2007 and reported that methylene blue "was a potent (tight binding) inhibitor for MAO A", that it "also inhibited MAO B but at much higher concentration", and that "at concentrations reported in the literature after intravenous administration, MAO B would be partially inhibited but MAO A would be completely inhibited", which they proposed as the mechanism of serotonin toxicity in patients on serotonin reuptake inhibitors.[11] Gillman's 2011 review of the case literature concluded that "13 of 14 of the reported cases of CNS toxicity were serotonin toxicity that met the Hunter Serotonin Toxicity Criteria" and that "all proposed uses of methylene blue entail levels that block monoamine oxidase".[12]

Zuschlag and colleagues' 2018 systematic review identified 50 published cases of methylene blue-associated serotonin syndrome, most "related to peri-operative use of MB in parathyroidectomies or for the treatment of vasoplegic shock", with concurrent serotonergic antidepressant treatment "described in all 50 cases", one fatality, and every prior case parenteral; the authors added a case they attribute to an oral methylene blue-containing urinary analgesic.[13] FDA's Summary Review states that "numerous cases of serotonin syndrome in patients who received methylene blue while on serotonergic medications have been reported to the FDA Adverse Event Reporting System (AERS) database", that in 2011 the agency warned of serious CNS reactions with "methylene blue in any formulation", and that the clinical reviewer recommended "a Boxed Warning for the risk of serotonin syndrome with concomitant use of serotonergic drugs"; the current boxed warning, revised in November 2023, also names opioids.[1][4]

The ProvayBlue label describes the approved product, its indication and its warnings

Drugs@FDA records NDA 204630 for ProvayBlue (methylene blue) injection, sponsor Provepharm SAS, with original approval on 8 April 2016 and orphan designation.[2] The approval letter states that the application "is approved under the provisions of accelerated approval regulations (21 CFR 314.500)", that such products "require further adequate and well-controlled studies to verify and describe clinical benefit", and lists postmarketing requirement PMR-3065-1.[14] The Summary Review gives the background: "methylene blue is a marketed unapproved drug that has been used for many decades to treat patients with acquired methemoglobinemia", and the application "was based on retrospective case reports and a review of the literature".[4] Drugs@FDA records an efficacy supplement approved on 8 January 2024, and the current label reports the prospective study and registry that followed the original approval; ProvayBlue is listed as the reference listed drug, and the first generic methylene blue injection was approved on 5 December 2023.[1][2][3]

The current label, revised February 2024, reports efficacy from 31 adults across an open-label single-arm study (NCT03395223) and an observational registry (NCT03542760): of the 28 subjects with a baseline methemoglobin measurement, 26 "had at least a 50% reduction in metHB from baseline in their first assessment post baseline".[1] Serious adverse reactions occurred in 3.2 percent of those patients, and reactions at or above 2 percent "included headache, hypokalemia, diarrhea, hypomagnesemia, myoclonus, nausea, and seizure-like phenomena".[1] The label contraindicates the drug in severe hypersensitivity to any thiazine dye and in glucose-6-phosphate dehydrogenase deficiency "due to the risk of hemolytic anemia", and states that it "may cause fetal harm when administered to a pregnant woman".[1]

Label sectionWhat the ProvayBlue label states
Boxed warningSerious or fatal serotonergic syndrome with serotonergic drugs and opioids; avoid concomitant use with SSRIs, SNRIs, MAOIs and opioids
IndicationTreatment of pediatric and adult patients with acquired methemoglobinemia
ContraindicationsSevere hypersensitivity to methylene blue or any thiazine dye; G6PD deficiency because of hemolytic anemia risk
Warnings 5.2 to 5.4Anaphylactic reactions reported; methemoglobinemia may not resolve or may rebound; hemolysis can occur during treatment
Warnings 5.5 to 5.7Pulse oximetry underestimates oxygen saturation; confusion, dizziness and visual disturbance; blue dye in urine interferes with laboratory tests
Pregnancy and lactationMay cause fetal harm; discontinue breast-feeding during and for up to 8 days after treatment because of genotoxicity
Nonclinical toxicologyPancreatic islet adenomas or carcinomas in male rats in a two-year oral study; genotoxic in the Ames test and two in vitro mammalian assays
PharmacokineticsHalf-life of approximately 24 hours; about 40 percent excreted unchanged in urine; metabolized by CYP1A2, 2C19 and 2D6 in vitro with UGT conjugation predominant; Azure B formed as a metabolite

The pharmacodynamics section states that the exposure-response and exposure-safety relationships for methylene blue are unknown.[1] A phase I study in 16 healthy volunteers by Walter-Sack and colleagues, run to support oral use against malaria, reported 72.3 percent absolute bioavailability for an aqueous oral formulation.[15]

What the human neuroimaging and memory studies report

Rodriguez and colleagues enrolled 26 healthy adults in a randomized, double-blinded, placebo-controlled functional MRI trial of a single low oral dose and reported that methylene blue "increased response in the bilateral insular cortex during a psychomotor vigilance task", increased response during a short-term memory task in prefrontal, parietal and occipital cortex, and produced "a 7% increase in correct responses during memory retrieval".[5] Telch and colleagues randomized 42 adults with marked claustrophobic fear to methylene blue or placebo after extinction training and reported that participants with low fear at the end of training "showed significantly less fear at the 1-month follow-up if they received methylene blue", while those with moderate to high residual fear "tended to fare worse".[16]

Alda and colleagues ran a six-month double-blind crossover trial in 37 participants with bipolar disorder on lamotrigine and reported that the active dose "significantly improved symptoms of depression" and anxiety, that effects on cognitive symptoms "were not significant", and that the medication "was well tolerated with transient and mild side-effects".[17] Each of these trials is small, and none was designed to assess the serotonergic interaction the label describes.[5][16][17]

The largest human exposure comes from the tau aggregation inhibitor program. Wischik and colleagues' exploratory phase 2 trial randomized 321 participants with mild or moderate Alzheimer's disease to three oral regimens of methylthioninium or placebo and reported an ADAS-cog effect at 24 weeks in the moderate subgroup at the middle regimen, with delivery of the highest regimen "impaired due to dose-dependent dissolution and absorption limitations"; ClinicalTrials.gov records 323 enrolled under NCT00515333.[18][19] Gauthier and colleagues then randomized 891 participants with mild to moderate Alzheimer's disease to the reduced form, leuco-methylthioninium, in a 15-month phase 3 trial at 115 centers and reported that "the prespecified primary analyses did not show any treatment benefit at either of the doses tested for the coprimary outcomes", with gastrointestinal and urinary effects the most common adverse events and dose-dependent hemoglobin reductions the most common laboratory abnormality; the registration is NCT01689246.[6][20] That trial excluded patients on medicines carrying methemoglobinemia warnings "because the oxidised form of methylthioninium in high doses has been shown to induce this condition".[6]

The critical care trials report hemodynamic effects in a different population

A 2024 meta-analysis by Pruna and colleagues identified 11 randomized trials of intravenous methylene blue in 556 critically ill and perioperative patients with vasodilatory hypotension; across the nine trials that reported mortality it found lower mortality in the methylene blue group (risk ratio 0.60), and it also reported shorter intensive care and hospital stays and higher mean arterial pressure, while concluding that "further adequately powered randomized trials are needed to confirm these findings".[21] Zuschlag's review places most serotonin syndrome reports in the same perioperative setting.[13]

The skin-aging literature is in vitro, and the catalog item is a topical combination cream

The published work on methylene blue and skin aging is concentrated in cultured fibroblasts and reconstructed skin models, with the Xiong 2017 paper the principal citation, and no randomized trial of a topical methylene blue preparation for skin aging was located in PubMed on 8 November 2026.[7] The approved product is an intravenous injection, so its label carries no information on topical exposure.[1] The reviews note that the dye stains tissue and that its photochemistry is part of its pharmacology.[8][9]

The compounded item in ExaVeyra's catalog is a topical cream that pairs methylene blue with estriol, prepared by the 503A pharmacy partner; its listing and specifications are on the product page rather than here.

Methylene blue meets the section 503A bulk substance conditions through its USP monograph

Section 503A(b)(1)(A) permits a licensed pharmacist or physician to compound using bulk drug substances that comply with an applicable USP or NF monograph or, "if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary", or otherwise appear on the 503A bulks list; the substance must also be "manufactured by an establishment that is registered under section 360" and "accompanied by valid certificates of analysis for each bulk drug substance".[22] Methylene blue is the subject of a United States Pharmacopeia monograph (the approved injection is labeled "USP"), so clause (I) is the operative condition, and it has also been a component of an FDA-approved drug since 8 April 2016; either way, the 503A bulks list is not the operative condition for it as of 8 November 2026.[1][2][22] The statute's remaining conditions still apply: the preparation may not appear on FDA's list of drugs withdrawn or removed from the market as unsafe or not effective, the pharmacy may not compound "regularly or in inordinate amounts" any drug products that are "essentially copies of a commercially available drug product", and the preparation may not be one FDA has identified by regulation as presenting "demonstrable difficulties for compounding". The significant difference determination is left to "the prescribing practitioner".[22]

The evidence position and the documents a practice holds

The label, the FDA review and the pharmacology reviews agree that methylene blue is a redox dye and a potent MAO-A inhibitor at the exposures the approved and studied uses produce.[1][4][11][12] The human data outside methemoglobinemia consist of small randomized trials and a tau aggregation program whose phase 3 trial was negative, and the skin data are in vitro.[5][6][7] The documents a practice would hold follow from those statements.[1][22]

  • The valid prescription order for the identified patient, or the prescriber's notation that a compounded product is necessary for that patient, as section 503A(a) describes.
  • A medication review against the label's interaction list in the boxed warning and section 5.1: serotonergic antidepressants, monoamine oxidase inhibitors, opioids and dextromethorphan, as the label states them.
  • The pharmacy's certificate of analysis for the methylene blue bulk substance, which section 503A requires for each bulk drug substance.
  • A record that the preparation is a compounded product rather than an FDA-approved one, and that the approved product's label describes intravenous use for acquired methemoglobinemia only.

ExaVeyra's methylene blue preparation reaches a practice through a licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis for each lot available on request. Whether to use it, in which patient and with what monitoring are decisions for the prescribing practitioner.

This article summarizes publicly available federal regulation for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.

Annotated References

Numbered in the order they are cited in the text. Each source is annotated with what it supports on this page; peer-reviewed articles are listed with journal, volume, issue and pages, and primary sources are regulations, agency documents, guidelines and position statements.

  1. 1.Official sourceDailyMed, PROVAYBLUE (methylene blue) injection, prescribing information (American Regent for Provepharm SAS; label revised February 2024, SPL version 28). Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6848e5-35ed-4046-b13c-3032b5ba3232
  2. 2.RegulatoryFDA, Drugs@FDA: NDA 204630, ProvayBlue (methylene blue) injection, approval history (original approval 8 April 2016). Accessed 8 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204630
  3. 3.RegulatoryFDA, Drugs@FDA: ANDA 215636, methylene blue injection, intravenous (first generic approval referencing ProvayBlue, 5 December 2023). Accessed 9 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215636
  4. 4.RegulatoryFDA Center for Drug Evaluation and Research, Summary Review, Application Number 204630Orig1s000 (ProvayBlue). Accessed 8 November 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/204630Orig1s000SumR.pdf
  5. 5.Peer-reviewedRodriguez P, Zhou W, Barrett DW, Altmeyer W, Gutierrez JE, Li J, Lancaster JL, Gonzalez-Lima F, Duong TQ. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. 2016;281(2):516-526. https://pubmed.ncbi.nlm.nih.gov/27351678/Annotation: Randomized, double-blinded, placebo-controlled fMRI trial in 26 healthy adults: increased insular and prefrontal-parietal-occipital activity during attention and memory tasks and a 7 percent increase in correct memory retrieval.
  6. 6.Peer-reviewedGauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873-2884. https://pubmed.ncbi.nlm.nih.gov/27863809/Annotation: Fifteen-month phase 3 trial of leuco-methylthioninium in 891 participants at 115 centers: no treatment benefit on either coprimary outcome, gastrointestinal and urinary adverse events, dose-dependent hemoglobin reductions, and exclusion of patients on methemoglobinemia-warning drugs.
  7. 7.Peer-reviewedXiong ZM, O'Donovan M, Sun L, Choi JY, Ren M, Cao K. Anti-Aging Potentials of Methylene Blue for Human Skin Longevity. Scientific Reports. 2017;7(1):2475. https://pubmed.ncbi.nlm.nih.gov/28559565/Annotation: Cultured human fibroblasts and a reconstructed 3D skin model: ROS scavenging, delayed senescence, increased hydration and dermis thickness, and elastin and collagen 2A1 upregulation; the principal skin citation and entirely in vitro.
  8. 8.Peer-reviewedOz M, Lorke DE, Hasan M, Petroianu GA. Cellular and molecular actions of Methylene Blue in the nervous system. Medicinal Research Reviews. 2011;31(1):93-117. https://pubmed.ncbi.nlm.nih.gov/19760660/Annotation: The physicochemical basis of methylene blue's actions (planar structure, redox chemistry, ionic charge, light spectrum), the cGMP pathway as its most significant effect, and its multiple cellular targets.
  9. 9.Peer-reviewedSchirmer RH, Adler H, Pickhardt M, Mandelkow E. "Lest we forget you--methylene blue...". Neurobiology of Aging. 2011;32(12):2325.e7-16. https://pubmed.ncbi.nlm.nih.gov/21316815/Annotation: Methylene blue as the first synthetic drug with a 120-year history of medical and staining uses, and the renewed interest in it as an antimalarial and a tau aggregation inhibitor.
  10. 10.Peer-reviewedTucker D, Lu Y, Zhang Q. From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue. Molecular Neurobiology. 2018;55(6):5137-5153. https://pubmed.ncbi.nlm.nih.gov/28840449/Annotation: The mitochondrial electron-shuttling hypothesis (NADH to cytochrome c, increased complex IV activity) and the statement that the neuroprotection evidence comes from in vitro and animal studies.
  11. 11.Peer-reviewedRamsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology. 2007;152(6):946-951. https://pubmed.ncbi.nlm.nih.gov/17721552/Annotation: Kinetic assays on purified human enzyme showing methylene blue is a potent tight-binding reversible MAO-A inhibitor, with MAO-A completely inhibited at concentrations reported after intravenous use.
  12. 12.Peer-reviewedGillman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. Journal of Psychopharmacology. 2011;25(3):429-436. https://pubmed.ncbi.nlm.nih.gov/20142303/Annotation: The review finding that 13 of 14 reported CNS toxicity cases met the Hunter Serotonin Toxicity Criteria and that all proposed uses of methylene blue reach MAO-blocking levels.
  13. 13.Peer-reviewedZuschlag ZD, Warren MW, K Schultz S. Serotonin Toxicity and Urinary Analgesics: A Case Report and Systematic Literature Review of Methylene Blue-Induced Serotonin Syndrome. Psychosomatics. 2018;59(6):539-546. https://pubmed.ncbi.nlm.nih.gov/30104021/Annotation: Systematic review of 50 published serotonin syndrome cases, all parenteral and all with concurrent serotonergic antidepressants, one fatal, plus a case the authors attribute to an oral methylene blue-containing product.
  14. 14.RegulatoryFDA, NDA 204630 approval letter to Provepharm SAS, accelerated approval under 21 CFR 314.500 (April 2016). Accessed 8 November 2026. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/204630Orig1s000ltr.pdf
  15. 15.Peer-reviewedWalter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, Meissner P, Mikus G. High absolute bioavailability of methylene blue given as an aqueous oral formulation. European Journal of Clinical Pharmacology. 2009;65(2):179-189. https://pubmed.ncbi.nlm.nih.gov/18810398/Annotation: Phase I crossover study in 16 healthy volunteers, run to support oral use against malaria, reporting 72.3 percent absolute oral bioavailability.
  16. 16.Peer-reviewedTelch MJ, Bruchey AK, Rosenfield D, Cobb AR, Smits J, Pahl S, Gonzalez-Lima F. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. American Journal of Psychiatry. 2014;171(10):1091-1098. https://pubmed.ncbi.nlm.nih.gov/25018057/Annotation: Randomized double-blind trial in 42 adults with claustrophobic fear: methylene blue after a successful exposure session reduced fear at one month, and after an unsuccessful session tended to worsen it.
  17. 17.Peer-reviewedAlda M, McKinnon M, Blagdon R, Garnham J, MacLellan S, O'Donovan C, Hajek T, Nair C, Dursun S, MacQueen G. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. British Journal of Psychiatry. 2017;210(1):54-60. https://pubmed.ncbi.nlm.nih.gov/27284082/Annotation: Six-month double-blind crossover trial in 37 adults with bipolar disorder on lamotrigine: improved depression and anxiety ratings, no significant cognitive effect, transient mild side effects.
  18. 18.Peer-reviewedWischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. Journal of Alzheimer's Disease. 2015;44(2):705-720. https://pubmed.ncbi.nlm.nih.gov/25550228/Annotation: Exploratory double-blind, placebo-controlled dose-finding trial of methylthioninium in 321 participants with mild or moderate Alzheimer's disease: an ADAS-cog effect in the moderate subgroup at the middle regimen and impaired delivery of the highest regimen.
  19. 19.Official sourceClinicalTrials.gov, NCT00515333, TRx0014 in Patients With Mild or Moderate Alzheimer's Disease (TauRx Therapeutics; 323 enrolled, completed December 2007). Accessed 8 November 2026. https://clinicaltrials.gov/study/NCT00515333
  20. 20.Official sourceClinicalTrials.gov, NCT01689246, Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease (TauRx Therapeutics; 891 enrolled, completed November 2015). Accessed 8 November 2026. https://clinicaltrials.gov/study/NCT01689246
  21. 21.Peer-reviewedPruna A, Bonaccorso A, Belletti A, Turi S, Di Prima AL, D'amico F, Zangrillo A, Kotani Y, Landoni G. Methylene Blue Reduces Mortality in Critically Ill and Perioperative Patients: A Meta-Analysis of Randomized Trials. Journal of Cardiothoracic and Vascular Anesthesia. 2024;38(1):268-274. https://pubmed.ncbi.nlm.nih.gov/37880041/Annotation: Eleven randomized trials in 556 critically ill and perioperative patients with vasodilatory hypotension: lower mortality across the nine trials reporting it (risk ratio 0.60), shorter stays, higher mean arterial pressure, with a call for adequately powered trials.
  22. 22.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm

Cite this page

ExaVeyra Sciences Editorial Team. Methylene Blue: Pharmacology and Human Data. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/methylene-blue-pharmacology-human-data. Accessed [date accessed].

ExaVeyra Exclusive Member Resources

For verified and approved practicesReserved for clinicians

Research Vault

Curated peer-reviewed literature for each catalog compound, with a printable two-minute brief, evidence at a glance and the papers to start with.

  • 266 peer-reviewed papers, each with its DOI or PubMed link
  • 8 research areas
  • 128 systematic reviews, meta-analyses and randomized trials
  • 18 compounds with a two-minute brief

Registration takes about two minutes. Access opens after NPI verification and a review by our team. No payment details.

Each brief opens with the strongest study designs first, then the newest.

Common questions

What is methylene blue approved for in the United States?
The reference listed drug, ProvayBlue (methylene blue) injection, NDA 204630, is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia, and FDA has approved generic methylene blue injections since December 2023. ProvayBlue was approved on 8 April 2016 under the accelerated approval regulations with orphan designation, after decades in which methylene blue was, in FDA's words, a marketed unapproved drug.
What does the ProvayBlue boxed warning say?
The boxed warning states that ProvayBlue may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids, and directs clinicians to avoid concomitant use with SSRIs, SNRIs, monoamine oxidase inhibitors and opioids. The warning section adds that dextromethorphan may increase the risk, that some reported cases were fatal, and that patients should not take serotonergic drugs within 72 hours after the last dose.
Why does methylene blue interact with antidepressants?
Ramsay, Dunford and Gillman showed in 2007 that methylene blue is a potent, tight-binding reversible inhibitor of monoamine oxidase A, and that at concentrations reached after intravenous administration MAO-A would be completely inhibited. FDA's review of the ProvayBlue application describes methylene blue as a potent MAO inhibitor with substantial potential for adverse drug interactions, and the published case reviews attribute the serotonin syndrome cases to that property.
What did the 2011 FDA safety communication say?
FDA's Summary Review of the ProvayBlue application records that in 2011 the agency issued a safety communication warning that serious central nervous system reactions may occur when methylene blue in any formulation is administered to patients taking serotonergic drugs, citing numerous serotonin syndrome reports in its adverse event database. The original communication pages were not retrievable from fda.gov on 8 November 2026, so this page reports them as the Summary Review describes them.
What have the human memory and neuroimaging studies found?
The studies are small. A randomized functional MRI trial in 26 healthy adults reported increased task-related brain activity and better memory retrieval after a single low oral dose; a trial in 42 adults with claustrophobia reported that the effect on fear extinction depended on how successful the exposure session had been; and a crossover trial in 37 adults with bipolar disorder reported improved depressive and anxiety symptoms without a significant effect on cognition. The one large phase 3 trial, of the reduced form in 891 participants with Alzheimer's disease, did not meet its coprimary endpoints.
Is there clinical evidence for topical methylene blue on skin?
The published skin work is in cultured human fibroblasts and a reconstructed three-dimensional skin model, where Xiong and colleagues reported reactive oxygen species scavenging, delayed cellular senescence and increased elastin and collagen expression. No randomized trial of a topical methylene blue preparation for skin aging was located in PubMed on 8 November 2026, and the approved product's label describes intravenous use only.
How may a 503A pharmacy compound methylene blue?
Section 503A allows compounding from bulk drug substances that meet an applicable USP or NF monograph or, if no monograph exists, are components of FDA-approved drugs or appear on the 503A bulks list. The substance must also be manufactured by an FDA-registered establishment and accompanied by a valid certificate of analysis. Methylene blue has a USP monograph and has been a component of an approved drug since 2016, so it does not depend on the 503A bulks list. The preparation must still be made for an identified patient on a valid prescription, and the pharmacy may not compound regularly or in inordinate amounts any drug product that is essentially a copy of a commercially available drug product.

This page is provided for informational purposes only. It is not medical advice, it is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for the judgment of a licensed practitioner. Consult a healthcare professional before acting on anything stated here. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. These references report what trials, reviews, product labels and FDA communications state about compounds that a 503A pharmacy partner prepares, for professional education, and make no statement about the suitability of any product for any patient. Where this page discusses an FDA-approved product, the approved labeling governs and nothing here modifies it. Compounded preparations are a separate product class: they are not FDA-approved finished drug products, they are prepared under section 503A of the Federal Food, Drug, and Cosmetic Act against a patient-specific prescription, and they are prescription products supplied to licensed practitioners only. Cosmetic ingredients discussed here are described within the cosmetic regulatory frame and are not drugs. The prescribing decision rests with the licensed practitioner. Read the full notice

Reference only. Not legal or medical advice.

The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

Read the full notice